|
|
Blood, 15 September 2006, Vol. 108, No. 6, pp. 2081-2086.
Prepublished online as a Blood First Edition Paper on May 30, 2006; DOI 10.1182/blood-2006-04-015859.
Previous Article | Next Article 
Submitted December 22, 2005
Accepted May 8, 2006
Fetal hemoglobin silencing in humans
Patricia A Oneal, Nicole M Gantt, Joseph D Schwartz, Natarajan V Bhanu, Y T Lee, John W Moroney, Christopher H Reed, Alan N Schechter, Naomi L Luban, and Jeffery L Miller*
National Institutes of Diabetes, Digestive & Kidney Diseases, National Institutes of Health, MD, USA
Department of Obstetrics & Gynecology, National Naval Medical Center, Bethesda, MD, USA
Laboratory Medicine and Pathology, Children's National Medical Center, Washington, DC, USA
* Corresponding author; email: jm7f{at}nih.gov.
Interruption of the normal fetal-to-adult transition of
hemoglobin expression should largely ameliorate sickle
cell and beta-thalassemia syndromes. Achievement of this
clinical goal requires a robust understanding of gamma-
globin gene and protein silencing during human
development. For this purpose, age-related changes in
globin phenotypes of circulating human erythroid cells
were examined from 5 umbilical cords, 99 infants, and 5
adult donors. Unexpectedly, an average of 95% of the cord
blood erythrocytes and reticulocytes expressed HbA and the
adult beta-globin gene, as well as HbF and the
gamma-globin genes. The distribution of hemoglobin and
globin gene expression then changed abruptly due to the
expansion of cells lacking HbF or gamma-globin mRNA
(HbF/gamma-globin silenced cells). In adult reticulocytes,
less than 5% expressed gamma-globin mRNA. These data are
consistent with a " switching" model in humans
that initially largely results from gamma- and beta-globin
gene co-expression and competition during fetal
development. In contrast, early post-natal life is marked
by the rapid accumulation of cells that possess
undetectable gamma-globin mRNA and HbF. The silencing
phenomenon is mediated by a mechanism of cellular
replacement. This novel silencing pattern may be important
for the development of HbF-enhancing therapies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. N. Schechter
Hemoglobin research and the origins of molecular medicine
Blood,
November 15, 2008;
112(10):
3927 - 3938.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dijon, F. Bardin, A. Murati, M. Batoz, C. Chabannon, and C. Tonnelle
The role of Ikaros in human erythroid differentiation
Blood,
February 1, 2008;
111(3):
1138 - 1146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-H. Goh, M. Josleyn, Y. T. Lee, R. L. Danner, R. B. Gherman, M. C. Cam, and J. L. Miller
The human reticulocyte transcriptome
Physiol Genomics,
July 18, 2007;
30(2):
172 - 178.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Coleman and B. Inusa
Sickle Cell Anemia: Targeting the Role of Fetal Hemoglobin in Therapy
Clinical Pediatrics,
June 1, 2007;
46(5):
386 - 391.
[Abstract]
[PDF]
|
 |
|
|
|